We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biocorp | EU:ALCOR | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 35.10 | 28.50 | 35.10 | 0.00 | 01:00:00 |
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, today announces its annual results for the year ended on December 31, 2022, as approved by the Board of directors on March 27th.
Eric Dessertenne, CEO of BIOCORP, commented: "More products, more partnerships and more geographical areas to cover. In a macro-economic environment that remains as complex as ever, we have managed to make it on three levels this year. First, on the industrial and commercial level, with the strengthening of strategic positions for our connected devices, whether with our historical or recent partners: Sanofi, Merck, Novo Nordisk and Becton Dickinson. Secondly, on the regulatory front, 2022 has enabled us to reach a crucial milestone with the FDA’s 510k clearance, making our Mallya connected device the only one in its class to be cleared on both sides of the Atlantic Ocean. Finally, at the strategic level, our vision of the connected health devices market has been strengthened. This market, dynamic but still in its infancy, appears today to all our interlocutors as an obvious necessity due to the constant pressure on healthcare systems (increase in the cost of treatments, consideration of compliance by payers). More than ever, BIOCORP is recognized by the major industry players as a trusted partner to embark on the path to digital health. In this general context, our revenues, which still come mainly from the receipt of milestone payments, increased last year by more than 12%. As for our result, slightly negative at € -0.6 million, it results mainly from the strong increase in fees related to regulatory affairs (patent filings in all territories) and expenses related to the internationalization of our device deliveries (compatibility tests). However, the EBITDA remains positive at € 42.9K. In conclusion, 2022 was a year of growth investments reflecting our internationalization. 2023 will also be marked by a high level of investment with the extension of our production site in Issoire and by a gradual transition to a model of recurring revenues from the sale of our connected devices.”
Key financial data on 12/31/2022
In €
31/12/2022
31/12/2021
Sales
11 670 405
10 225 314
Other operating income
177 783
328 411
Total operating income
11 848 188
10 553 725
Operating expenses
External purchase and expenses
802 110
417 781
Taxes, duties, and other levies
4 700 143
3 944 614
Wages and expenses
6 010 074
5 051 671
Other operating expenses
1 067 961
1 002 252
Total operating expenses
12 580 288
10 416 318
Net operating income
42 904
936 817
Net financial income
-732 100
137 408
Exceptionnal income
-60 932
-89 641
Research Tax Credit and Innovation Tax Credit
-116 736
48 560
Total operating expenses
258 589
197 908
Net Result
-651 179
294 234
Closing cash position
2 666 352
1 845 602
2022 Highlights
Outlook 2023
- Expansion of the Issoire production site: 30% increase in production area and areas dedicated to connected devices, notably Mallya and Injay.
- Continuing the partnership dynamic and gradual transition to a recurring revenue model from the sale of our range of devices.
- Reinforced investments in software and services to offer complete digital solutions to the pharmaceutical industry and to accelerate the deployment of our connected devices.
The 2022 annual financial report is available on the Company's website.
ABOUT BIOCORP Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 80 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR). For more information, please visit www.biocorp.fr.
Disclaimer
This press release is for information purposes only. This press release does not constitute, and shall not be deemed to constitute, an offer to the public, an offer to subscribe, an offer to sell or a solicitation of interest in a transaction by way of public offering of financial securities in any jurisdiction.
Financial securities may be offered or sold in the United States only pursuant to registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from such registration requirement. The securities of the Company that are the subject of this press release have not been and will not be registered under the Securities Act, and the Company does not intend to conduct a public offering of the securities that are the subject of this press release in the United States.
The release, publication, or distribution of this press release in some countries may violate applicable laws. The information contained in this press release does not constitute an offer of securities in France, the United States, Canada, Australia, Japan or any other country. This press release may not be published, transmitted, or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230328005658/en/
BIOCORP
Sylvaine Dessard Marketing & Communication Director rp@biocorp.fr + 33 (0)6 88 69 72 85
Bruno ARABIAN barabian@ulysse-communication.com +33 (0)6 87 88 46 26
1 Year Biocorp Chart |
1 Month Biocorp Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions